Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth

Executive Summary

Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.

You may also be interested in...



Teva’s Cubicin Authorized Generic Is First Rival To Merck’s Brand

Teva launched an authorized generic version of Merck’s blockbuster antibiotic, while Pfizer did not provide an update on the timeline of a generic launch for which a court decision paved the way.

Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?

Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.

Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)

Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel